NCCN Task Force Report: Bone Health and Cancer Care

Restricted access

Higher incidences of osteoporosis and osteopenia are found in cancer patients, particularly in women receiving aromatase inhibitors or with chemotherapy-induced ovarian failure, or in men with prostate cancer and androgen deprivation therapy. Therefore, management of long-term bone health is emerging as an important aspect of comprehensive cancer care. Patients with cancer typically have a number of additional risk factors for osteoporosis that should prompt screening, regardless of patient age or sex. Maintaining bone health requires a broad knowledge base, including understanding underlying bone metabolism and how it is affected by both cancer itself and the drugs used to treat cancer, the effect of chemotherapy-induced menopause on bone health, bone markers and imaging techniques used to assess bone health, therapeutic strategies to maintain bone health, and treatment of bone metastases, including surgery for pathologic fractures. Multiple members of the healthcare team may need to be involved in education and care of the patient. This report summarizes discussion of these and other issues regarding bone health and cancer care from the NCCN Bone Health and Cancer Care Task Force meeting in early 2006. (JNCCN 2006;4(Suppl 2):S1-S24)

  • 1.

    Cooper C, Atkinson EJ, Jacobsen SJ, . Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:10011005.

  • 2.

    Hillner BE, Ingle JN, Chlebowski RT, . American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:40424057.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Tham YL, Sexton K, Kramer R, . The adherence of practice guidelines in the assessment of bone health in women with chemotherapy-induced amenorrhea. San Antonio Breast Cancer Symposium 2005, Abstract # 6070.

    • Search Google Scholar
    • Export Citation
  • 4.

    Green AD, Colon-Emeric CS, Bastian L. Does this woman have osteoporosis? JAMA 2004;292:2890900.

  • 5.

    Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:529541.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Raisz LG. Clinical practice: Screening for osteoporosis. N Engl J Med 2005;353:164171.

  • 7.

    Kanis JA, McCloskey EV, Powles T, . A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:11791181.

  • 8.

    Chen Z, Maricic M, Bassford TL, . Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med 2005;165: 552558.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000;15:183187.

  • 10.

    Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:18891897.

  • 11.

    Siris ES, Miller PD, Barrett-Connor E, . Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment. JAMA 2001;286: 28152822.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Miller PD, Barlas S, Brenneman SK, . An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004;164:11131120.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, . Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000;26:505511.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Christgau S. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem 2000;46:431.

  • 15.

    Eastell R, Mallinak N, Weiss S, . Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15: 594598.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Clowes JA, Hannon RA, Yap TS, . Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886890.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Chestnut CH, Bell NH, Clark GS, . Hormone replacement therapy in postmenopausal women: Urinary Ntelopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102:2937.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Ravn P, Clemmesen B, Christinasen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24: 237244.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Mouritzen, Buclin T, Cosma Rochat M, . Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in health volunteers. J Bone Miner Res 2002; 17:14781485.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    NIH Consensus Statement. Optimal calcium intake. 1994;12:131.

  • 21.

    Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699706.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Lips P. Vitamin D deficiency and secondary hyperparathyriodism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Rev 2001;22: 477501.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Chapuy MC, Arlot ME, Duboeuf F, . Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:16371642.

  • 24.

    Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670676.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Grant AM, Avenell A, Campbell MK, . Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebocontrolled trial. Lancet 2005;365:16211628.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Porthouse J, Cockayne S, King C, . Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005;330:1003.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Jackson RD, LaCroix AZ, Gass M, . Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006:354;339.

  • 28.

    Cummings SR, Karpf DB, Harris F . Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 2002;112:281289.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Ettinger B, Black DM, Mitlak BH, . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282: 637645.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Black DM, Cummings SR, Karpf DB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:15351541.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    McClung MR, Geusens P, Miller PD, . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344: 333340.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Delmas PD, Recker RR, Chesnut CH, . Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int 2004;15:792798.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Thiebaud D, Burckhardt P, Melchior J, . Two years’ effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in postmenopause. Osteoporos Int 1994;4:7683.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Thiebaud D, Burckhardt P, Kriegbaum H, . Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298307.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Fuleihan Gel -H, Salamoun M, Mourad YA, . Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005;90: 32093214.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Swenson KK, Henly SJ, Shapiro AC, Schroeder LM. Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer. Clin J Oncol Nurs 2005;9:177184.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Smith MR, McGovern FJ, Zeitman AL, . Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948955.

  • 38.

    Diamond TH, Winters J, Smith A, . The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:14441450.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Smith MR, Eastham J, Gleason DM, . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:20082012.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Saad F, Gleason DM, Murray R, . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:14581468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Hortobagyi GN, Theriault RL, Porter L, . Efficacy of pamidronate in reducing skeletal-related complications in patients with breast cancer and lytic bone lesions. N Engl J Med 1996;335:17851791.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    Hortobagyi GN, Theriault RL, Lipton A, . for the Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:20382044.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Lipton A, Demers L, Curley E, . Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021206.

  • 44.

    Theriault RL, Lipton A, Hortobagyi GN, .: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomised, placebocontrolled trial. J Clin Oncol 1999;17:846854.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Neer RM, Arnaud CD, Zanchetta JR, . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:14341441.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Van Poznak C, Sauter S. Clinical management of osteoporosis in women with a history of breast cancer. Cancer 2005;104:443456.

  • 47.

    Meunier PJ, Roux C, Seeman E, . The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350: 459468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Reginster JY, Seeman E, De Vernejoul MC, . Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 2005;90:28162822.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006:24;675

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50.

    Love RR, Mazess RR, Barden HS, . Effects of tamoxefen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852856.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51.

    Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490495.

  • 52.

    Bekker PJ, Holloway DL, Rasmussen AS, . A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:10591066.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    McClung MR, Lewiecki EM, Cohen SB, . Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821831.

  • 54.

    Goodwin PJ, Ennis M, Pritchard KI, . Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:23652370.

  • 55.

    Fornier MN, Modi S, Panageas KS, . Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104: 15751579.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000;343:10861094.

  • 57.

    Shapiro CL, Phillips G, Van Poznak CH, . Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2005;90:4146.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Anders CK, Snyder SA, Barrier RC, . Inhibin A and B as predictive markers for chemotherapy-induced premature ovarian failure (POF) among premenopausal women with early stage breast cancer (ESBC). San Antonio Breast Cancer Symposium 2005. Abstract #1027.

  • 59.

    Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19:33063311.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Powles TJ, McCloskey E, Paterson AH, . Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90:704708.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Saarto T, Blomqvist C, Valimaki M, . Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:13411347.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Delmas PD, Balena R, Confravreux E, . Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a doubleblind, placebo-controlled study. J Clin Oncol 1997;15: 955962.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Howell A, on behalf of the ATAC Trialists’ Group A. ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. 2004 San Antonio Breast Cancer symposium, Abstract #1.

  • 64.

    Thurlimann B, Keshaviah A, Coates AS, . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:27472757.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Coombes RC, Hall E, Gibson LJ . Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:10811092.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Coombes RC, Hall E, Snowdon CF, . The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. 2004 San Antonio Breast Cancer Symposium, Abstract #3.

  • 67.

    Goss PE, Ingle JN, Martino S, . A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:17931802.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Gnant M, Jakesz R, Minerritsch B, . Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopauasl breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole vs. gosereline plus tamoxifen. San Antonio Breast Cancer Symposium 2004, Abstract #6.

  • 69.

    Brufsky A, Harker W, Beck J, . Zoledronic acid effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women with early breast cancer receiving adjuvant Letrozole: 12 mos BMD results of the Z-FAST trial. 2005 ASCO Annual Meeting, Abstract #533.

  • 70.

    Powles T, McCloskey E, Kurkilahti M, . Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. 2004 ASCO Annual Meeting, Abstract #528.

  • 71.

    Mittan D, Lee S, Miller E, Perez RC, . Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87: 36563661.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154164.

  • 73.

    Smith MR, Lee WC, Brandman J, . Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897903.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 74.

    Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:38413846.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Brown JE, Cook RJ, Major P, . Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:5969.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Dearnaley DP, Sydes MR, Mason MD, . A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:13001311.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Kang Y, Siegel PM, Shu W . A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537549.

  • 78.

    Yin JJ, Selander K, Chirgwin JM, . TGF-signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103: 197206.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 79.

    Yang YA, Dukhanina O, Tang B, . Lifetime exposure to a soluble TGF- antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:16071615.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Kang Y, He W, Tulley S, . Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005;102:1390913914.

  • 81.

    Muraoka RS, Dumont N, Ritter CA . Blockade of TGF- inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 2002;109:15511559.

  • 82.

    Uhl M, Aulwurm S, Wischhusen J, . SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:79547961.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Hayashi T, Hideshima T, Nguyen AN, . Transforming growth factor beta receptor I kinase inhibitor downregulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004;10:75407546.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 84.

    Denton CP, Lindahl GE, Khan K, . Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRIIδk). J Biol Chem 2005;280: 1605316065.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Yin JJ, Mohammad KS, Kakonen SM, . A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100: 1095410959.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Carducci MA, Padley RJ, Breul J, . Effect of endothelin-A receptor blockade with atraxentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679689.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Nelson JB. Endothelin inhibition: novel therapy for prostate cancer. J Urol 2003;170:S65S67.

  • 88.

    Guise TA, Kozlow WM, Heras-Herzig A, . Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005;5(Suppl 2):S4653.

  • 89.

    Hamaoka T, Madewell JE, Podoloff DA, . Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22: 29422953.

  • 90.

    Ward WG, Holsenbeck S, Dorey FJ, . Metastatic disease of the femur: Surgical treatment. Clin Orthop Relat Res 2003;415(Suppl):S230244.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 91.

    Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 1989;249:256264.

    • Search Google Scholar
    • Export Citation
  • 92.

    Samsani SR, Panikkar V, Venu KM, . Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail. Eur J Surg Oncol 2004; 30:993997.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Moholkar K, Mohan R, Grigoris P. The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases. Acta Orthop Belg 2004;70:429434.

    • Search Google Scholar
    • Export Citation
  • 94.

    Marco RA, Sheth DS, Boland PJ, . Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am 2000;82:642651.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Benevenia J, Cyran FP, Biermann JS, . Treatment of advanced metastatic lesions of the acetabulum using the saddle prosthesis. Clin Orthop Relat Res 2004;426: 2331.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 96.

    Redmond BJ, Biermann JS, Blasier RB. Interlocking intramedullary nailing of pathological fractures of the shaft of the humerus. J Bone Joint Surg Am 1996;78A:891896.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 97.

    Franck WM, Olivieri M, Jannasch O, Hennig FF. An expandable nailing system for the management of pathological humerus fractures. Arch Orthop Trauma Surg 2002;122: 400405.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Clohisy DR, Le CT, Cheng EY. Evaluation of the feasibility of and results of measuring health-status changes in patients undergoing surgical treatment for skeletal metastases. J Orthop Res 2000;18:19.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Talbot M, Turcotte RE, Isler M, . Function and health status in surgically treated bone metastases. Clin Orthop Relat Res 2005;438:215220.

  • 100.

    Dijstra S, Wiggers T, van Geel BN, Boxma H. Impending and actual pathological fractures in patients with bone metastases of the long bones: A retrospective study of 233 surgically treated fractures. Eur J Surg 1994;160:535542.

    • Search Google Scholar
    • Export Citation
  • 101.

    Goetz MP, Callstrom MR, Charboneau JW, . Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004;22:300306.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 102.

    Marcy PY, Palussiere J, Descamps B, . Percutaneous cementoplasty for pelvic bone metastasis. Support Care Cancer. 2000;8:500503.

  • 103.

    Kelekis A, Lovblad KO, Mehdizade A, . Pelvic osteoplasty in osteolytic metastases: technical approach under fluoroscopic guidance and early clinical results. J Vasc Interv Radiol 2005;16:8188.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Weill A, Kobaiter H, Chiras J. Acetabulum malignancies: technique and impact on pain of percutaneous injection of acrylic surgical cement. Eur Radiol 1998;8:123129.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Fourney DR, Schomer DF, Nader R, . Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003;98:2130.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Lane JM, Hong R, Koob J, . Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Relat Res 2004;426:4953.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 107.

    Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998;25: 13621367.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 108.

    Serafini AN, Houston SJ, Resche I, . Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:15741581.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Sartor O, Reid RH, Hoskin PJ, . Samarium-153Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63: 940945.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 55 55 21
PDF Downloads 8 8 1
EPUB Downloads 0 0 0